CHAIN Secures Seed Funding and Appoints New Board Members

December 23, 2015

London, UK, 23 December, 2015

CHAIN has successfully completed its first round of seed funding last month with the support of a consortium of business angels based in the UK. Business angels are investors who bring expertise and provide start-up capital.  CHAIN will use the funds to strengthen its unique technology platform based on the development of advanced microbes for the production of high value chemicals.

Board Appointments

CHAIN also welcomes Robert Rickman and Paul Green to the Board of Directors. Mr Rickman will act as Chair and Mr Green joins as a non-executive director. Mr Rickman is a Partner in Rockley Group and holds MA and MSc degrees from the University of Oxford. He is a director at Schroder UK Midcap Investment Trust plc and Carclo plc, as well as a number of private companies. Mr Green has over 25 years of professional management experience with leading multinationals in global and Middle East-focused roles.

New board appointees meet with CHAIN founders at Imperial College. From left to right, newly appointed Chairperson, Robert Rickman; CHAIN CEO, Edward Green; Non-Executive Director, Paul Green; and CHAIN CCO, Basil Omar.

Dr Edward Green, Chief Executive of CHAIN, comments, “We are delighted to complete our first investment which provides early validation of our business model.  I am also pleased to welcome Paul and Robert to the Board. Both have a wealth of financial and business acumen that will prove invaluable as CHAIN transitions from an early stage business towards a technology and market leader in Industrial Biotechnology.”


CHAIN operates at two sites; Imperial College, London and the SBRC at the University of Nottingham.

Central to CHAIN’s business proposition is the provision of a New and Advanced Anaerobic Fermentation Technology Platform for a variety of Industrial Biotechnology products and applications. CHAIN are very interested in forming development partnerships with companies interested in novel reductive enzymes, anti-microbials, bio-polymers & fine/speciality chemicals.  To discuss how our CHAIN’s platform may offer advantages for your particular applications contact Business Development manager Ben Bradley.


Media contact:

Dr David Kirk